You just read:

Biohaven's Positive Phase 3 Trial of Rimegepant Zydis® Orally Dissolving Tablet for Acute Treatment of Migraine Published in The Lancet

News provided by

Biohaven Pharmaceutical Holding Company Ltd.

Jul 15, 2019, 07:30 ET